ArticleInfection and drug resistance2023
Characteristics of TB/HIV Co-Infection and Patterns of Multidrug-Resistance Tuberculosis in the Northwest Amhara, Ethiopia.
Article in Infection and drug resistance, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 18 citations in OpenAlex.
- Global and regional trends in multidrug- or rifampicin-resistant tuberculosis, 2000-2024 with forecasts to 2030: a systematic review and meta-analysis.BMC infectious diseases · 2026Pooled it
- Multidrug Resistance Tuberculosis in the Context of Co-Infection in Ethiopia: A Systematic Review and Meta-Analysis.Journal of epidemiology and global health · 2025Pooled it
- Sexual Wellbeing and Urinary Tract Infections: A Scoping Review.International urogynecology journal · 2026Review
- Prevalence and associated factors of rifampicin resistance pulmonary tuberculosis among HIV-positive patients in Bahir Dar, Northwest, Ethiopia.Scientific reports · 2026Article
- Prevalence of drug resistant tuberculosis and its associated factors among tuberculosis patients at wolkite health center in central Ethiopia.Scientific reports · 2026Article
- Epidemiology and treatment outcomes of TB-HIV co-infection in a rural South African setting: an exploratory analysis of retreatment and contextual factors.Frontiers in public health · 2026Article
- Influence of Diabetes Mellitus on the Development of Multidrug-Resistant Tuberculosis (MDR-TB) in Relation With Genetic Mutations ofThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2026Article
- Association of D516V, H526Y, and S531L rpoB gene polymorphisms and risk factors with rifampicin resistance in Mycobacterium tuberculosis isolates from pulmonary TB patients in Northwest Amhara, Ethiopia: cross-sectional study.BMC infectious diseases · 2025Article
- Global burden of MDR-TB and XDR-TB: trends, inequities, and future implications for public health planning.BMC infectious diseases · 2025Article
- Article
- Article
- Predicting Treatment Outcomes in Patients with Drug-Resistant Tuberculosis and Human Immunodeficiency Virus Coinfection, Using Supervised Machine Learning Algorithm.Pathogens (Basel, Switzerland) · 2024Article
- Breaking barriers: The potential of nanosystems in antituberculosis therapy.Bioactive materials · 2024Review
- Article
- Insights into the in-vitro Susceptibility and Drug-Drug Interaction Profiles Against Drug-Resistant and SusceptibleInfection and drug resistance · 2024Article
- Molecular characterization of genetic mutations with fitness loss in pulmonary tuberculosis patients associated with HIV co-infection in Northwest Amhara, Ethiopia.SAGE open medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Multidrug-resistant tuberculosis (MDR-TB) has continued to be a serious public health threat and significantly challenges global TB control and prevention efforts, where the TB/HIV co-infection epidemic makes the situation much worse. The aim of the study was to determine the determinant factors associated with patterns of MDR-TB among pulmonary TB patients in the Northwest Amhara, Ethiopia. Methods: A hospital-based cross-sectional study was conducted from May 2022 to February 2023 in the Northwest Amhara, Ethiopia. Data on the participants' socio-demographics and clinical characteristics were obtained using a pre-tested checklist. Phenotypic susceptibility testing to first-line anti-TB drugs was performed on 180 isolates by automated BD BACTEC MGIT 960 system. Logistic regression analysis was performed to determine the association of risk factors with patterns of MDR-TB. A p-value ≤0.05 was considered statistically significant. Results: The overall proportion of TB with HIV co-infected cases was 19.8% (50/252). Culture positivity was confirmed in 203/252 (80.6%) of sputum samples. Among 168 isolates, the DST showed that 119 (70.8%) isolates were pan-susceptible to all first-line drugs and prevalence of any resistance to first-line drugs was 49,168 (29.2%). Among the resistant isolates, 28 (16.7%) were any mono-resistance and 12 (7.1%) were determined to be resistant to MDR-TB. TB with a previous TB treatment (aOR = 6.73, 95% CI: 1.78-25.47, p = 0.005) and HIV co-infected (aOR = 0.252, 95% CI: 0.73-0.875, p = 0.03) were significantly associated with MDR-TB. Conclusion: Higher prevalence of TB and MDR-TB was examined among TB patients in the study area. In the study, history of previous TB treatment was the strongest risk factor MDR-TB infection followed by TB with HIV co-infected cases. Therefore, there is a need of strengthening TB control and prevention programs to reduce the increase of TB incidence, further emergence and transmission of a public health threat of MDR-TB cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.